SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus
Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company
pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment of inflammatory
bowel disease (IBD), today announced the closing of its
initial public offering of 11,500,000 shares of common stock, which
includes the exercise in full by the underwriters of their option
to purchase 1,500,000 additional shares, at a public offering price
of $19.00 per share. All of the
shares were offered by Prometheus. The aggregate gross proceeds
from the offering, before deducting underwriting discounts and
commissions and other offering expenses payable by Prometheus, were
$218.5 million. Prometheus' common
stock is listed on the Nasdaq Global Select Market under the ticker
symbol "RXDX".
SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities
acted as joint bookrunning managers for the offering.
Registration statements relating to the offering have been filed
with the Securities and Exchange Commission (SEC) and became
effective on March 11, 2021. A
prospectus relating to and describing the terms of the offering has
been filed with the SEC and is available on the SEC's website at
www.sec.gov. The offering was made only by means of a prospectus.
Copies of the final prospectus may be obtained from SVB Leerink
LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, or by
telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@svbleerink.com; or from Credit Suisse Securities
(USA) LLC, Attention: Prospectus
Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at
(800) 221-1037, or by email at usa.prospectus@credit-suisse.com; or
from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, Attn:
Syndicate, or by phone at (415) 364-2720 or by email at
syndprospectus@stifel.com; or from Guggenheim Securities LLC,
Attention: Equity Syndicate Department, 330 Madison Avenue,
New York, NY 10017, by telephone
at (212) 518-5548 or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a biotechnology company
pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment and diagnosis of
IBD. The company's precision medicine platform, Prometheus360,
combines proprietary bioinformatics discovery methods with one of
the world's largest gastrointestinal bioinformatics databases to
identify novel therapeutic targets and develop therapeutic
candidates to engage those targets.
Prometheus is headquartered in San
Diego, CA.
View original
content:http://www.prnewswire.com/news-releases/prometheus-biosciences-announces-closing-of-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301248704.html
SOURCE Prometheus Biosciences